MultiCell Immunotherapeutics Data Demonstrates Potential to Prevent Avian Flu; Pre-Clinical Mouse Models Show 1,000-fold Reduction in Viral Load in H1N1 Strain.

LINCOLN, R.I. -- MultiCell Technologies, Inc. (OTCBB: MCET) announced today that pre-clinical tests conducted by scientists at MultiCell's San Diego laboratories showed that MultiCell Immunotherapeutics, Inc.'s (MCTI's) toll receptor technology was able to reduce pulmonary virus titers by 1,000- fold in the H1N1 strain of flu to barely detectable levels. These results indicate that the technology may be able to reduce viral load in avian influenza. The H5N1 avian flu contains many of the same proteins as the H1N1 strain of flu, so the HINI results are projected to be important to the understanding of developing an immunotherapeutic against avian flu.

MCTI's toll receptor technology employs double stranded RNA (dsRNA) and targets toll receptors 3,7 and 8. In studies of mouse models, the viral load was reduced by more than 90%. The results of the study showed that more than 100,000 units of pulmonary viral titers were reduced to negligible levels after administration of the immunotherapeutic. The Company plans additional pre-clinical trials to further evaluate the methodology and plans to approach the Centers for Disease Control and Prevention to conduct further studies. MultiCell acquired the technology as a result of its acquisition last month of substantially all of the assets of Astral, Inc.

"The pre-clinical results in mouse models support our view that our toll receptor technology may be able to respond to threats posed by agents such as avian influenza. We believe that these results highlight the commercial opportunities for our immunotherapeutics," said Dr. Stephen Chang, President of MultiCell Technologies Inc. "The recent acquisition of the assets of Astral has broadened our intellectual property platform considerably, and provides us with additional promising therapeutic opportunities."

About Avian Flu

Avian influenza attacks and destroys the human respiratory system and "... kills 55% of the people it infects," according to Laurie Garrett, senior fellow for global health at the Council on Foreign Relations. Avian flu can be contracted by bird, animal or human contact or airborne. It can spread at a rate three times faster than normal flu. For the newer strain of the disease, H5N1, there are no antibodies; this virus could pose a greater threat than smallpox, AIDS or anthrax.

About MultiCell Technologies, Inc.

MultiCell Technologies is a developer of therapies, an adult stem cell company and a supplier of immortalized cell lines for drug discovery applications. With its subsidiary, MultiCell Immunotherapeutics (MCTI), MultiCell intends to commercialize new therapeutics for the treatment of various diseases and disorders. MultiCell holds key patents relating to novel strategies for the isolation of adult human liver cells, and cell clusters or doublets as well as additional patents in the areas of stem cell technology, the Sybiol(TM) synthetic bio-liver therapeutic liver assist device, and immortalized human hepatocytes. MultiCell's stem cells are derived from adult tissues, which avoids the ethical and contamination issues associated with embryonic stem cells. MultiCell's headquarters and research laboratories are at 701 George Washington Highway, Lincoln, Rhode Island 02865.

For more information about MultiCell see http://www.multicelltech.com.

Caution Regarding Forward-Looking Statements

Any statements in this press release about MultiCell's expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). These statements are often, but not always, made through the use of words or phrases such as "believe," "will," "expect," "anticipate," "estimate," "intend," "plan," and "would." MultiCell bases these forward-looking statements on current expectations about future events. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by any forward-looking statement. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections in the forward-looking statement include, but are not limited to, the risk that the market for our products will not grow as expected, and the risk that our products will not achieve expectations. For additional information about risks and uncertainties we face, see documents we file with the SEC, including our Report on Form 10-KSB for the fiscal year ended November 30, 2004 and all our quarterly and other periodic SEC filings. MultiCell claims the protection of the safe harbor for forward-looking statements under the Act and assumes no obligation and expressly disclaims any duty to update any forward-looking statement to reflect events or circumstances after the date of this news release or to reflect the occurrence of subsequent events.